Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer
Phase 1
Terminated
- Conditions
- Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
- Interventions
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Precirix
- Target Recruit Count
- 13
- Registration Number
- NCT04467515
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients
Phase 1
Completed
- Conditions
- Healthy VolunteersBreast Cancer
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Precirix
- Target Recruit Count
- 9
- Registration Number
- NCT02683083
- Locations
- 🇧🇪
UZ Brussel, Brussels, Choose A State, Belgium
News
No news found